View in EDS PDF Full Text

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.

Saved in:
Bibliographic Details
Title: Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
Authors: Tron AE; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Belmonte MA; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; LifeMine Therapeutics, Cambridge, MA, USA., Adam A; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Surface Oncology, Cambridge, MA, USA., Aquila BM; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Alkermes, Inc., Waltham, MA, USA., Boise LH; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA., Chiarparin E; Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK., Cidado J; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Embrey KJ; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK., Gangl E; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Gibbons FD; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Gregory GP; School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, 3800, Australia.; Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia., Hargreaves D; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK., Hendricks JA; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Johannes JW; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Johnstone RW; Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.; The Sir Peter MacCallum Center, Department of Oncology, University of Melbourne, Parkville, VIC, 3000, Australia., Kazmirski SL; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Fulcrum Therapeutics, Cambridge, MA, USA., Kettle JG; Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK., Lamb ML; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Matulis SM; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA., Nooka AK; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA., Packer MJ; Oncology, IMED Biotech Unit, AstraZeneca, Alderley Park, SK10 4TG, UK., Peng B; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Rawlins PB; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK., Robbins DW; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Nurix, Inc., San Francisco, CA, USA., Schuller AG; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Su N; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Yang W; Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Ye Q; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Zheng X; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Secrist JP; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; LifeMine Therapeutics, Cambridge, MA, USA., Clark EA; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Wilson DM; Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK., Fawell SE; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Hird AW; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA. alexander.hird@astrazeneca.com.
Source: Nature communications [Nat Commun] 2018 Dec 17; Vol. 9 (1), pp. 5341. Date of Electronic Publication: 2018 Dec 17.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 30559424
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Tron+AE%22">Tron AE</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Belmonte+MA%22">Belmonte MA</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; LifeMine Therapeutics, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Adam+A%22">Adam A</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Surface Oncology, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Aquila+BM%22">Aquila BM</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Alkermes, Inc., Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Boise+LH%22">Boise LH</searchLink>; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA.<br /><searchLink fieldCode="AU" term="%22Chiarparin+E%22">Chiarparin E</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK.<br /><searchLink fieldCode="AU" term="%22Cidado+J%22">Cidado J</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Embrey+KJ%22">Embrey KJ</searchLink>; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK.<br /><searchLink fieldCode="AU" term="%22Gangl+E%22">Gangl E</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Gibbons+FD%22">Gibbons FD</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Gregory+GP%22">Gregory GP</searchLink>; School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, 3800, Australia.; Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.<br /><searchLink fieldCode="AU" term="%22Hargreaves+D%22">Hargreaves D</searchLink>; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK.<br /><searchLink fieldCode="AU" term="%22Hendricks+JA%22">Hendricks JA</searchLink>; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Johannes+JW%22">Johannes JW</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Johnstone+RW%22">Johnstone RW</searchLink>; Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.; The Sir Peter MacCallum Center, Department of Oncology, University of Melbourne, Parkville, VIC, 3000, Australia.<br /><searchLink fieldCode="AU" term="%22Kazmirski+SL%22">Kazmirski SL</searchLink>; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Fulcrum Therapeutics, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Kettle+JG%22">Kettle JG</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK.<br /><searchLink fieldCode="AU" term="%22Lamb+ML%22">Lamb ML</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Matulis+SM%22">Matulis SM</searchLink>; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA.<br /><searchLink fieldCode="AU" term="%22Nooka+AK%22">Nooka AK</searchLink>; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA.<br /><searchLink fieldCode="AU" term="%22Packer+MJ%22">Packer MJ</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Alderley Park, SK10 4TG, UK.<br /><searchLink fieldCode="AU" term="%22Peng+B%22">Peng B</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Rawlins+PB%22">Rawlins PB</searchLink>; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK.<br /><searchLink fieldCode="AU" term="%22Robbins+DW%22">Robbins DW</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Nurix, Inc., San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Schuller+AG%22">Schuller AG</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Su+N%22">Su N</searchLink>; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Yang+W%22">Yang W</searchLink>; Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Ye+Q%22">Ye Q</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Zheng+X%22">Zheng X</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Secrist+JP%22">Secrist JP</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; LifeMine Therapeutics, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Clark+EA%22">Clark EA</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Wilson+DM%22">Wilson DM</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK.<br /><searchLink fieldCode="AU" term="%22Fawell+SE%22">Fawell SE</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Hird+AW%22">Hird AW</searchLink>; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA. alexander.hird@astrazeneca.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2018 Dec 17; Vol. 9 (1), pp. 5341. <i>Date of Electronic Publication: </i>2018 Dec 17.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=30559424
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41467-018-07551-w
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 5341
    Titles:
      – TitleFull: Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Tron AE
      – PersonEntity:
          Name:
            NameFull: Belmonte MA
      – PersonEntity:
          Name:
            NameFull: Adam A
      – PersonEntity:
          Name:
            NameFull: Aquila BM
      – PersonEntity:
          Name:
            NameFull: Boise LH
      – PersonEntity:
          Name:
            NameFull: Chiarparin E
      – PersonEntity:
          Name:
            NameFull: Cidado J
      – PersonEntity:
          Name:
            NameFull: Embrey KJ
      – PersonEntity:
          Name:
            NameFull: Gangl E
      – PersonEntity:
          Name:
            NameFull: Gibbons FD
      – PersonEntity:
          Name:
            NameFull: Gregory GP
      – PersonEntity:
          Name:
            NameFull: Hargreaves D
      – PersonEntity:
          Name:
            NameFull: Hendricks JA
      – PersonEntity:
          Name:
            NameFull: Johannes JW
      – PersonEntity:
          Name:
            NameFull: Johnstone RW
      – PersonEntity:
          Name:
            NameFull: Kazmirski SL
      – PersonEntity:
          Name:
            NameFull: Kettle JG
      – PersonEntity:
          Name:
            NameFull: Lamb ML
      – PersonEntity:
          Name:
            NameFull: Matulis SM
      – PersonEntity:
          Name:
            NameFull: Nooka AK
      – PersonEntity:
          Name:
            NameFull: Packer MJ
      – PersonEntity:
          Name:
            NameFull: Peng B
      – PersonEntity:
          Name:
            NameFull: Rawlins PB
      – PersonEntity:
          Name:
            NameFull: Robbins DW
      – PersonEntity:
          Name:
            NameFull: Schuller AG
      – PersonEntity:
          Name:
            NameFull: Su N
      – PersonEntity:
          Name:
            NameFull: Yang W
      – PersonEntity:
          Name:
            NameFull: Ye Q
      – PersonEntity:
          Name:
            NameFull: Zheng X
      – PersonEntity:
          Name:
            NameFull: Secrist JP
      – PersonEntity:
          Name:
            NameFull: Clark EA
      – PersonEntity:
          Name:
            NameFull: Wilson DM
      – PersonEntity:
          Name:
            NameFull: Fawell SE
      – PersonEntity:
          Name:
            NameFull: Hird AW
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 17
              M: 12
              Text: 2018 Dec 17
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-electronic
              Value: 2041-1723
          Numbering:
            – Type: volume
              Value: 9
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nature communications
              Type: main
ResultId 1